{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:09:53Z","timestamp":1773148193670,"version":"3.50.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Medical Association of Thailand (Prasert Prasarttong-Osoth) Research Fund"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0180325","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T17:47:34Z","timestamp":1499276854000},"page":"e0180325","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax\u00ae) for osteoporosis treatment"],"prefix":"10.1371","volume":"12","author":[{"given":"Aasis","family":"Unnanuntana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atthakorn","family":"Jarusriwanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panupan","family":"Songcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"ref1","article-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","year":"2004"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbmr.1698","article-title":"Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention","volume":"27","author":"JA Eisman","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00198-008-0743-7","article-title":"The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study","volume":"20","author":"A Papaioannou","year":"2009","journal-title":"Osteoporos Int"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s00198-012-1931-z","article-title":"The burden of illness of osteoporosis in Canada","volume":"23","author":"JE Tarride","year":"2012","journal-title":"Osteoporos Int"},{"issue":"12","key":"ref5","first-page":"1528","article-title":"Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment","volume":"95","author":"C Pongchaiyakul","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis","volume":"89","author":"J Sanderson","year":"2016","journal-title":"Bone"},{"issue":"9041","key":"ref7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"DM Black","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"HG Bone","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-014-2929-5","article-title":"Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties","volume":"26","author":"N Hassler","year":"2015","journal-title":"Osteoporos Int"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2474-11-68","article-title":"Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study","volume":"11","author":"DT Grima","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1185\/03007995.2012.708326","article-title":"The effect of mandatory generic substitution on the safety of alendronate and patients' adherence","volume":"28","author":"PS Lai","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/2193-1801-2-550","article-title":"A critical review of brand and generic alendronate for the treatment of osteoporosis","volume":"2","author":"JP Brown","year":"2013","journal-title":"Springerplus"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"JA Kanis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"JA Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1302\/0301-620X.95B9.31562","article-title":"Do bisphosphonates inhibit direct fracture healing? A laboratory investigation using an animal model","volume":"95-B","author":"T Savaridas","year":"2013","journal-title":"Bone Joint J"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry","volume":"8","author":"S Baim","year":"2005","journal-title":"J Clin Densitom"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1015632114068","article-title":"Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol","volume":"11","author":"J Tidermark","year":"2002","journal-title":"Qual Life Res"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1023\/A:1026193812514","article-title":"Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures","volume":"12","author":"J Tidermark","year":"2003","journal-title":"Qual Life Res"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"CJ Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"MA Paggiosi","year":"2014","journal-title":"Osteoporos Int"},{"key":"ref21","first-page":"34","article-title":"Effects of Alendronate and Raloxifene on Bone Density and Bone Turnover Markers in Postmenopausal Women","volume":"17","author":"E Z\u00fclf\u012fkaro\u011flu","year":"2011","journal-title":"Gynecol Obstet Reprod Med"},{"issue":"2","key":"ref22","first-page":"287","article-title":"A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act","volume":"59","author":"EK Lietzan","year":"2004","journal-title":"Food Drug Law J"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"Importance of precision in bone density measurements","volume":"4","author":"SL Bonnick","year":"2001","journal-title":"J Clin Densitom"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"SR Cummings","year":"2002","journal-title":"Am J Med"},{"issue":"10","key":"ref25","first-page":"3537","article-title":"Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women","volume":"85","author":"SL Greenspan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"S Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1185\/03007990802648903","article-title":"In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US","volume":"25","author":"RJ Dansereau","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"e78153","DOI":"10.1371\/journal.pone.0078153","article-title":"Comparing tolerability and efficacy of generic versus brand alendronate: A randomized clinical study in postmenopausal women with a recent fracture","volume":"8","author":"JP van den Bergh","year":"2013","journal-title":"PLoS One"},{"key":"ref29","first-page":"51","article-title":"The clinical tolerability profile of alendronate","volume":"101","author":"N Watts","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in England","volume":"14","author":"PN Biswas","year":"2003","journal-title":"Osteoporos Int"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"ES Orwoll","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00198-011-1850-4","article-title":"The association between automatic generic substitution and treatment persistence with oral bisphosphonates","volume":"23","author":"O Strom","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"HC Bucher","year":"1999","journal-title":"JAMA"},{"issue":"14","key":"ref34","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","article-title":"Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect","volume":"282","author":"FA McAlister","year":"1999","journal-title":"JAMA"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0180325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:19:51Z","timestamp":1588969191000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0180325"}},"subtitle":[],"editor":[{"given":"Tuan Van","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0180325","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}